GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eloxx Pharmaceuticals Inc (OTCPK:ELOX) » Definitions » Shiller PE Ratio

Eloxx Pharmaceuticals (Eloxx Pharmaceuticals) Shiller PE Ratio : (As of Jun. 06, 2024)


View and export this data going back to 1998. Start your Free Trial

What is Eloxx Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Eloxx Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Eloxx Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eloxx Pharmaceuticals Shiller PE Ratio Chart

Eloxx Pharmaceuticals Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Eloxx Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Eloxx Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Eloxx Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eloxx Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eloxx Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Eloxx Pharmaceuticals's Shiller PE Ratio falls into.



Eloxx Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Eloxx Pharmaceuticals's E10 for the quarter that ended in Sep. 2023 is calculated as:

For example, Eloxx Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-1.31/129.8595*129.8595
=-1.310

Current CPI (Sep. 2023) = 129.8595.

Eloxx Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201312 -384.000 98.326 -507.151
201403 -696.000 99.695 -906.592
201406 -311.085 100.560 -401.726
201409 -304.000 100.428 -393.091
201412 -624.000 99.070 -817.933
201503 -72.000 99.621 -93.854
201506 -56.000 100.684 -72.227
201509 -16.000 100.392 -20.696
201512 -152.000 99.792 -197.797
201603 -120.000 100.470 -155.102
201606 -48.000 101.688 -61.298
201609 -40.000 101.861 -50.995
201612 -32.000 101.863 -40.795
201703 -72.000 102.862 -90.897
201706 -72.000 103.349 -90.469
201709 -24.000 104.136 -29.929
201712 0.000 104.011 0.000
201803 -12.400 105.290 -15.294
201806 -16.800 106.317 -20.520
201809 -12.800 106.507 -15.607
201812 -16.000 105.998 -19.602
201903 -13.200 107.251 -15.983
201906 -16.000 108.070 -19.226
201909 -12.800 108.329 -15.344
201912 -11.600 108.420 -13.894
202003 -14.000 108.902 -16.694
202006 -8.000 108.767 -9.551
202009 -6.400 109.815 -7.568
202012 -6.000 109.897 -7.090
202103 -8.800 111.754 -10.226
202106 -21.600 114.631 -24.469
202109 -4.400 115.734 -4.937
202112 -5.600 117.630 -6.182
202203 -5.360 121.301 -5.738
202206 -4.900 125.017 -5.090
202209 -3.470 125.227 -3.598
202212 -2.920 125.222 -3.028
202303 -2.880 127.348 -2.937
202306 -1.960 128.729 -1.977
202309 -1.310 129.860 -1.310

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eloxx Pharmaceuticals  (OTCPK:ELOX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Eloxx Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Eloxx Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Eloxx Pharmaceuticals (Eloxx Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
480 Arsenal Way, Watertown, MA, USA, 02472
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in the science of ribosome modulation, leveraging both its ZM chemistry technology platform and its library of novel aminoglycosides to develop novel oral small molecule Ribosome Modulating Agents (RMAs) and Eukaryotic Ribosome Selective Glycosides (ERSGs), for the treatment of rare and ultra-rare genetic diseases where patients have point nonsense genetic mutations that result in premature stop codons and less than full-length proteins. The ELX-02, the company's investigational drug product candidate, is a small molecule designed to restore the production of full-length functional proteins.
Executives
Sumit Aggarwal director, officer: PRESIDENT AND CEO 480 ARSENAL WAY, WATERTOWN MA 02472
Vijay Modur officer: HEAD OF R&D C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER ST., WALTHAM MA 02451
Lindsay Androski director C/O ELOXX PHARMACEUTICALS, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Gadi Veinrib director 12 MIKHA'EL NE'EMAN ST, TEL AVIV-YAFO L3 6958101
Steven D Rubin director OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Jasbir Seehra director C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER STREET, WALTHAM MA 02451
Zafrira Avnur director 210 ALLANDALE ST #1B, CHESTNUT HILL MA 02467
Alan Edmund Walts director 197 8TH STREET, APARTMENT 804, CHARLESTOWN MA 02129
Daniel E. Geffken officer: Chief Financial Officer DAMONMILL SQUARE, SUITE 6A, CONCORD MA 01742
Pontifax Iv Gp L.p. 10 percent owner 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax Management 4 G.p. (2015) Ltd. 10 percent owner 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax (israel) Iv, L.p. 10 percent owner 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax (china) Iv L.p. 10 percent owner 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax (cayman) Iv L.p. 10 percent owner 4 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Ran Nussbaum director C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404

Eloxx Pharmaceuticals (Eloxx Pharmaceuticals) Headlines

From GuruFocus

Eloxx Pharmaceuticals Announces Changes to Board of Directors

By GuruFocusNews GuruFocusNews 07-05-2022